Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Table 2 Trial efficacy endpoints: Change in extravascular lung water index between days 1 and 4 (primary outcome)

Population	Test	Placebo	Imatinib	Effect size	t/F-value	df	95% CI	P -value
ITT (n = 66)	T-test	− 1.37	− 1.18	0.19	− 0.13	41.63	− 3.16 to 2.77	0.90
PP (n = 49)	T-test	− 1.35	− 1.34	0.01	− 0.00	32.32	− 3.70 to 3.71	0.99
Sensitivity (n = 52)	T-test	− 1.34	− 1.17	0.17	− 0.10	35.07	− 3.64 to 3.30	0.92
ITT	ANCOVA	–	–	–	0.76	1	–	0.39

Table summarizing the primary endpoint analysis in the intention-to-treat (ITT) and per-protocol (PP) population, including the sensitivity analysis without imputation of missing data
ANCOVA analysis of covariance; CI confidence interval; df degrees of freedom, EVLWi extravascular lung water index in ml/kg; ITT intention-to-treat; PP per-protocol

ISSN: 1364-8535